Keywords: cytogen, announces, development, initiative, oncology, products, anglo-swedish

Cytogen announces development initiative for oncology products

Article | 15 January 2007

Anglo-Swedish drug major AstraZeneca has given AZD2171, its orally-active, highly-potent and selective vascular endothelial growth factor signaling inhibitor, the global ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Astra Zeneca

AstraZeneca

Go to company listing